In the SURPASS-1 trial, which included 478 patients with obesity and type 2 diabetes, Tirzepatide significantly reduced body weight by 11.3% after 52 weeks, compared to 2.4% with placebo
Semaglutid (Ozempic, Wegovy): Haftalk enjeksiyon olarak verilen bu ila, hem diyabet hem de obezite tedavisinde etkilidir
Semaglutide, on the other hand, is a medication that was first used to treat type 2 diabetes
CAS Number 2381089-83-2 Molecular Formula C221H342N46O68 Molecular Weight 4731.4 g/mol Half-Life ~6 days (research reports) Sources & References Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Jastreboff AM, et al
Starting doses from PlexusDx-partnered compounding pharmacies are precisely calibrated to match your prescription
Liraglutide uses a shorter C16 fatty-acid chain attached by a single glutamate spacer, while semaglutide uses a longer C18 diacid with a bifunctional gamma-glutamate and mini-PEG linker